drugset / Trial / NCT05030155

Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)

NCT05030155

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare mepolizumab-based regimen to conventional therapeutic strategy for remission induction in patients with Eosinophilic Granulomatosis with Polyangiitis.

Timeline

Start
2022-05-30
Primary completion
2025-11
Completion
2025-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Azathioprine Small molecule 1 mg/kg
Comparator Cyclophosphamide Other / unclassified
Subject Mepolizumab Monoclonal antibody 300 mg Subcutaneous